24 0 0 0 OA 4.JIKEI HEART研究

著者
三輪 宜一
出版者
一般社団法人 日本臨床薬理学会
雑誌
臨床薬理 (ISSN:03881601)
巻号頁・発行日
vol.39, no.5, pp.157-161, 2008 (Released:2009-02-05)
参考文献数
18
著者
矢船 明史 竹内 正弘 成川 衛
出版者
日本臨床薬理学会
雑誌
臨床薬理 (ISSN:03881601)
巻号頁・発行日
vol.31, no.6, pp.705-713, 2000-11-30 (Released:2010-06-28)
参考文献数
20
被引用文献数
1 or 0

Since nonlinear mixed effects model is statistically quite complicated, it is not possible to obtain the analytical forms of the marginal mean and its corresponding covariance matrix for observations. To circumvent this issue, a first-order Taylor series expansion is generally employed to approximate a nonlinear model with a linear form additive in inter-subject random effects. This linear approximation is based on the assumption that the parameter variation among subjects is negligible, which is quite hard to satisfy in actual clinical data analyses. Consequently, the linear approximation probably leads to inconsistent estimators. This paper describes the statistical issues regarding the first-order linear approximation in nonlinear mixed effects models.
著者
永井 恒司
出版者
一般社団法人 日本臨床薬理学会
雑誌
臨床薬理 (ISSN:03881601)
巻号頁・発行日
vol.2, no.2, pp.189-195, 1971-04-30 (Released:2010-06-28)
参考文献数
22
著者
矢船 明史 津谷 喜一郎
出版者
日本臨床薬理学会
雑誌
臨床薬理 (ISSN:03881601)
巻号頁・発行日
vol.27, no.3, pp.635-645, 1996-09-30 (Released:2010-06-28)
参考文献数
55
被引用文献数
4 or 2

There has been an increasing number of clinical reports in the West to suggest that hepatotoxic reactions can be induced by herbal preparations including skullcap of Scutellaria species. In Japan, the root of Scutellaria baicalensis (Scutellariae Radix) is used under the name of Ogon, which is included in many kinds of Kampo formulations, such as Sho-saiko-to widely used for treating hepatic disorders. Reviewing the Information on Adverse Reactions to Drugs published by the Ministry of Health and Welfare of Japan, we found 22 cases of liver and biliary system reactions caused by Kampo formulations from 1989 through 1993, and in 20 of the cases, six types of Kampo formulations including Ogon were suspected as the cause of the reactions. In two clinical reports of pulmonary damage due to Sho-saiko-to, Lymphocyte Stimulation Test indicated that Ogon was the causative factor for the damage. Although there have been no reports to indicate that Ogon can actually cause liver damage, the results of our review strongly suggest the necessity for surveillance of the possibility of hepatotoxic reactions caused by Ogon.
著者
後藤 伸之 月岡 理絵 八田 壽夫 政田 幹夫 北澤 式文
出版者
日本臨床薬理学会
雑誌
臨床薬理 (ISSN:03881601)
巻号頁・発行日
vol.27, no.2, pp.465-468, 1996-06-30 (Released:2010-06-28)
参考文献数
9

We performed a pharmacoepidemiological study on triazolam dependence with typical doses in out-patients of Fukui Medical School Hospital. We investigated the prescriptions (duration of treatment and total dose prescribed) for patients administered triazolam.The patients were classified according to the prescription pattern of this drug, Group 1: patients who had been prescribed triazolam daily, Group 2: those who had been allowed to take triazolam when they cannot sleep.Approximately 40% of all the patients had been prescribed triazolam for 8 months or longer, and were judged to be normal dose dependence. The prevalence of this dependence was apparently higher in group 1 than in group 2.
著者
堀井 俊宏
出版者
一般社団法人 日本臨床薬理学会
雑誌
臨床薬理 (ISSN:03881601)
巻号頁・発行日
vol.38, no.6, pp.413-415, 2007-11-30 (Released:2008-10-31)
参考文献数
2
被引用文献数
1 or 0
著者
神田 藍 川崎 淳史 森田 理恵子 武者 愛美 櫻田 大也 小林 江梨子 佐藤 信範
出版者
一般社団法人 日本臨床薬理学会
雑誌
臨床薬理 (ISSN:03881601)
巻号頁・発行日
vol.44, no.4, pp.313-318, 2013-07-31 (Released:2013-08-22)
参考文献数
10
被引用文献数
1 or 0

As the number of chronic kidney disease patients increases every year, a concomitant increase in drug use among patients with renal impairment is anticipated in daily clinical practice. For patient safety, drug information should be useful and meet the needs of medical workers. The aim of this study was to investigate the problem of the descriptions in package inserts of prescription drugs regarding: 1) drug administration to patients with renal impairment, and 2) effects of the drug on the kidney (hereinafter “information on renal function” ). Also, we evaluated the usefulness of the renal function information for medical workers. For this survey, 337 prescription drugs that require careful attention for use in patients with renal impairment were selected. We extracted “the information on renal function” described in the package inserts of these 337 prescription drugs from the website of Pharmaceuticals and Medical Devices Agency. We compared the contents of the information regarding the pharmacokinetics of patients with renal impairment described in the package insert with those described in the corresponding interview form. In 44.8% of the 337 package inserts, information on pharmacokinetics in patients with renal impairment was not included. Only 21.2% of the inserts contained useful information on drug administration to such patients, such as clear dose adjustment. Therefore, our survey suggests that the package inserts do not provide sufficient information on “renal function” for medical workers. In conclusion, improvement of the information regarding “renal function” in the prescription drug package inserts is necessary in order to meet the needs of medical workers. (Jpn J Clin Pharmacol Ther 2013; 44(4): 313-318)